Current Report Filing (8-k)
July 09 2018 - 5:46PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 6, 2018
TAURIGA
SCIENCES, INC.
(Exact
Name of Registrant as Specified in Charter)
Florida
|
|
000-53723
|
|
30-0791746
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
555
Madison Avenue
5th
Floor Suite 506
New
York, NY 10022
|
|
|
|
10022
|
(Address
of principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (917) 796-9926
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
3.03 Material Modifications to Rights of Securities Holders.
The
information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On
March 12, 2018, Tauriga Sciences, Inc. (the “Company”) held a meeting of its board of directors. The matters voted
on and approved at the meeting included an amendment to the Company’s Articles of Incorporation to decrease the number of
authorized shares of the Company’s common stock, $0.00001 par value per share (the “Common Stock”) from 7,500,000,000
to 100,000,000 shares and to effect a reverse stock split of the Company’s Common Stock at a ratio of 1-for-75 (the “Reverse
Stock Split”).
On
June 8, 2018, the Company filed Articles of Amendment to its Articles of Incorporation (the “Amendment”) with the
Secretary of State of the State of Florida to decrease the number of authorized shares of the Company’s Common Stock from
7,500,000,000 to 100,000,000 and to effect a 1-for-75 reverse stock split of the Company’s Common Stock. The Reverse Stock
Split became effective at 12:01 a.m. on July 9, 2018. A copy of the Amendment is attached hereto as Exhibit 3.1 and incorporated
herein by reference.
As
a result of the Reverse Stock Split, each seventy-five (75) shares of the Company’s issued and outstanding Common Stock
has been automatically combined and converted into one (1) issued and outstanding share of Common Stock. The Reverse Stock Split
has affected all issued and outstanding shares of Common Stock, as well as Common Stock underlying stock options, warrants and
other convertible securities outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock
Split has reduced the number of outstanding shares of the Common Stock outstanding prior to the Reverse Stock Split from 4,078,179,672
shares to 54,377,316 shares immediately following the stock split.
No
fractional shares will be issued as a result of the Reverse Stock Split, and any such stockholders whose number of post-split
shares would result in a fractional number will have his/her/its shares rounded up to the next number of shares.
ClearTrust,
LLC is acting as exchange agent for the Reverse Stock Split and will send instructions to stockholders of record who hold stock
certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who
hold their shares in brokerage accounts or “street name” are not required to take any action to effect the exchange
of their shares.
On
July 6, 2018, the Company issued a press release announcing the Reverse Stock Split. A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Date:
July 9, 2018
|
TAURIGA
SCIENCES, INC.
|
|
|
|
|
By:
|
/s/
Seth M. Shaw
|
|
Name:
|
Seth
M. Shaw
|
|
Title:
|
Chief
Executive Officer
|
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tauriga Sciences (CE) (USOTC:TAUG)
Historical Stock Chart
From Apr 2023 to Apr 2024